Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen.
B cell maturation antigen
CD138
CD19
CD38
SLAMF7/CS1
chimeric antigen receptor-modified T cells
immunotherapy
multiple myeloma
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2019
2019
Historique:
received:
03
02
2019
accepted:
28
06
2019
entrez:
6
8
2019
pubmed:
6
8
2019
medline:
21
10
2020
Statut:
epublish
Résumé
Chimeric antigen receptor (CAR)-modified T cell therapy is a rapidly emerging immunotherapeutic approach that is revolutionizing cancer treatment. The impressive clinical results obtained with CAR-T cell therapy in patients with acute lymphoblastic leukemia and lymphoma have fueled the development of CAR-T cells targeting other malignancies, including multiple myeloma (MM). The field of CAR-T cell therapy for MM is still in its infancy, but remains promising. To date, most studies have been performed with B cell maturation antigen (BCMA)-targeted CARs, for which high response rates have been obtained in early-phase clinical trials. However, responses are usually temporary, and relapses have frequently been observed. One of the major reasons for relapse is the loss or downregulation of BCMA expression following CAR-T therapy. This has fostered a search for alternative target antigens that are expressed on the MM cell surface. In this review, we provide an overview of myeloma target antigens other than BCMA that are currently being evaluated in pre-clinical and clinical studies.
Identifiants
pubmed: 31379824
doi: 10.3389/fimmu.2019.01613
pmc: PMC6646459
doi:
Substances chimiques
B-Cell Maturation Antigen
0
Receptors, Antigen, T-Cell
0
Receptors, Chimeric Antigen
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1613Références
Nat Rev Cancer. 2002 Mar;2(3):175-87
pubmed: 11990854
Br J Haematol. 2002 Jun;117(4):882-5
pubmed: 12060125
Blood. 2004 Jan 15;103(2):689-94
pubmed: 14512299
Blood. 2004 Mar 15;103(6):2332-6
pubmed: 14630803
Blood. 2004 Apr 15;103(8):3148-57
pubmed: 15070697
Haematologica. 2005 Apr;90(4):489-93
pubmed: 15820944
Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19051-6
pubmed: 16365285
Blood. 2007 Feb 1;109(3):1185-92
pubmed: 17038522
Cancer Res. 2008 Jan 1;68(1):190-7
pubmed: 18172311
J Clin Oncol. 2008 Jun 1;26(16):2737-44
pubmed: 18443352
Clin Cancer Res. 2008 May 1;14(9):2775-84
pubmed: 18451245
Oncogene. 2008 Oct 6;27(45):5944-58
pubmed: 18836475
Blood. 2009 Mar 12;113(11):2498-507
pubmed: 19056691
Eur J Haematol. 2009 Aug;83(2):119-29
pubmed: 19456850
Gene Ther. 2010 May;17(5):678-86
pubmed: 20200563
Immunol Lett. 2011 Jan 30;134(2):129-36
pubmed: 20933013
Annu Rev Immunol. 2011;29:665-705
pubmed: 21219180
Blood. 2011 Apr 21;117(16):4304-14
pubmed: 21304103
Nat Rev Cancer. 2011 Apr;11(4):254-67
pubmed: 21390059
N Engl J Med. 2011 Mar 17;364(11):1046-60
pubmed: 21410373
Haematologica. 2011 Oct;96(10):1512-20
pubmed: 21606160
Leukemia. 2012 Feb;26(2):365-7
pubmed: 21836610
Blood. 2011 Oct 27;118(17):4519-29
pubmed: 21841166
Leukemia. 2012 Jun;26(6):1402-5
pubmed: 22094583
Gene Ther. 2013 Apr;20(4):386-95
pubmed: 22739387
Int J Oncol. 2012 Sep;41(3):876-84
pubmed: 22766978
Blood. 2013 Jan 10;121(2):318-28
pubmed: 23169779
PLoS One. 2012;7(12):e51851
pubmed: 23284789
Clin Cancer Res. 2013 Apr 15;19(8):1917-9
pubmed: 23444214
Cytometry B Clin Cytom. 2013 Jul-Aug;84(4):222-8
pubmed: 23450831
Oncoimmunology. 2013 Feb 1;2(2):e23037
pubmed: 23524451
Blood. 2013 Nov 14;122(20):3461-72
pubmed: 24016461
Leukemia. 2014 Apr;28(4):917-27
pubmed: 24067492
Matrix Biol. 2014 Apr;35:215-22
pubmed: 24145151
Mol Oncol. 2014 Mar;8(2):297-310
pubmed: 24388357
Clin Cancer Res. 2014 Aug 1;20(15):3989-4000
pubmed: 24677374
J Clin Oncol. 2015 Feb 20;33(6):540-9
pubmed: 25154820
Blood. 2015 Jun 25;125(26):4017-23
pubmed: 25999455
Hum Vaccin Immunother. 2015;11(7):1606-11
pubmed: 26001047
Cancer Immunol Res. 2015 Jun;3(6):575-82
pubmed: 26041808
J Immunol. 2015 Jul 15;195(2):736-48
pubmed: 26071561
Nat Med. 2015 Aug;21(8):914-921
pubmed: 26193344
Cytometry B Clin Cytom. 2016 Jan;90(1):81-90
pubmed: 26287276
Sci Transl Med. 2015 Sep 2;7(303):303ra139
pubmed: 26333935
N Engl J Med. 2015 Sep 10;373(11):1040-7
pubmed: 26352815
Br J Haematol. 2016 Mar;172(5):685-98
pubmed: 26791002
Haematologica. 2016 May;101(5):616-25
pubmed: 26858358
Blood. 2016 Jun 23;127(25):3225-36
pubmed: 27127303
J Clin Invest. 2016 Jul 1;126(7):2588-96
pubmed: 27270177
Blood. 2016 Sep 29;128(13):1688-700
pubmed: 27412889
Leukemia. 2017 Feb;31(2):382-392
pubmed: 27479184
Haematologica. 2017 Apr;102(4):785-795
pubmed: 28034989
Clin Transl Immunology. 2016 Dec 09;5(12):e116
pubmed: 28090317
Cancer Cell. 2017 Mar 13;31(3):396-410
pubmed: 28262554
Clin Lung Cancer. 2017 Jan;18(1):68-76.e2
pubmed: 28341109
Nature. 2017 Apr 27;544(7651):493-497
pubmed: 28424516
Blood. 2017 Jun 22;129(25):3386-3388
pubmed: 28476749
Mol Ther. 2017 Aug 2;25(8):1946-1958
pubmed: 28506593
Nature. 2017 May 24;545(7655):423-431
pubmed: 28541315
Ann Hematol. 2017 Aug;96(8):1407-1410
pubmed: 28577043
Front Immunol. 2017 Jul 24;8:892
pubmed: 28791027
Am J Cancer Res. 2017 Aug 01;7(8):1637-1641
pubmed: 28861320
Leukemia. 2018 Feb;32(2):402-412
pubmed: 28951562
Clin Cancer Res. 2018 Jan 1;24(1):106-119
pubmed: 29061640
Blood. 2017 Dec 28;130(26):2838-2847
pubmed: 29089311
Nat Med. 2017 Dec;23(12):1436-1443
pubmed: 29106400
Int J Cancer. 2018 May 1;142(9):1738-1747
pubmed: 29119551
Blood. 2018 Feb 15;131(7):746-758
pubmed: 29284597
Mol Ther. 2018 Feb 7;26(2):354-365
pubmed: 29310916
Front Immunol. 2018 Mar 21;9:507
pubmed: 29619024
JCI Insight. 2018 Apr 19;3(8):null
pubmed: 29669947
Nat Med. 2018 Jun;24(6):739-748
pubmed: 29808007
J Clin Oncol. 2018 Aug 1;36(22):2267-2280
pubmed: 29812997
PLoS One. 2018 May 30;13(5):e0197349
pubmed: 29847570
Best Pract Res Clin Haematol. 2018 Jun;31(2):147-157
pubmed: 29909915
J Exp Clin Cancer Res. 2018 Jul 21;37(1):163
pubmed: 30031396
Leukemia. 2019 Feb;33(2):426-438
pubmed: 30135465
Front Immunol. 2018 Aug 10;9:1821
pubmed: 30147690
Mol Pharm. 2018 Oct 1;15(10):4577-4588
pubmed: 30185037
Am Soc Clin Oncol Educ Book. 2018 May 23;38:e6-e15
pubmed: 30231373
Cancer Cell. 2018 Oct 8;34(4):596-610.e11
pubmed: 30300581
Clin Immunol. 2018 Oct 13;:null
pubmed: 30326256
Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):29-34
pubmed: 30340993
Cancer Immunol Res. 2019 Jan;7(1):100-112
pubmed: 30396908
Br J Cancer. 2019 Jan;120(1):26-37
pubmed: 30413825
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Front Immunol. 2018 Nov 28;9:2722
pubmed: 30546360
J Hematol Oncol. 2018 Dec 20;11(1):141
pubmed: 30572922
Ann Hematol. 2019 Apr;98(4):813-822
pubmed: 30693373
J Clin Invest. 2019 Mar 21;129(6):2210-2221
pubmed: 30896447
Front Oncol. 2019 Mar 12;9:146
pubmed: 30915277
Sci Transl Med. 2019 Mar 27;11(485):null
pubmed: 30918115
Nature. 2019 Apr;568(7750):112-116
pubmed: 30918399
Proc Natl Acad Sci U S A. 2019 May 7;116(19):9543-9551
pubmed: 30988175
Mol Ther. 2019 Jun 5;27(6):1126-1138
pubmed: 31005597
J Clin Invest. 2019 Apr 29;129(6):2175-2177
pubmed: 31033482
Oncotarget. 2019 Mar 22;10(24):2369-2383
pubmed: 31040928
N Engl J Med. 2019 May 2;380(18):1726-1737
pubmed: 31042825